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Background: This study aimed to test the hypothesis that immune dysfunction and the increased risk of
spontaneous abortion in pregnant women with hyperandrogenia (HA) are caused by the reduced tolerogenic
potential of dendritic cells (DCs) that results from elevated levels of dehydroepiandrosterone sulfate (DHEAS).
Methods: The phenotypic and functional properties of monocyte-derived DCs generated from blood monocytes
from non-pregnant women, women with a normal pregnancy, or pregnant women with HA, as well as the in vitro
effects of DHEAS on DCs in healthy pregnant women were investigated.
Results: In a normal pregnancy, DCs were shown to be immature and are characterized by a reduced number of
CD83+ and CD25+ DCs, the ability to stimulate type 2 T cell responses and to induce T cell apoptosis. By contrast,
DCs from pregnant women with HA had a mature phenotype, were able to stimulate both type 1 (IFN-γ) and type
2 (IL-4) T cell responses, and were characterized by lower B7-H1 expression and cytotoxic activity against CD8+
T cells. The addition of DHEAS to cultures of DCs from healthy pregnant women induced the maturation of DCs
and increased their ability to activate type 1 T cell responses.
Conclusion: Our data demonstrated the reduction in the tolerogenic potential of DCs from pregnant women with
HA, and revealed new mechanisms involved in the hormonal regulation of DCs mediated by DHEAS.
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The hypothesis that tolerance plays a major role in preg-
nancy was first proposed by P. B. Medawar more than
50 years ago [1]. Subsequent studies not only confirmed
the assumptions of Medawar, but also resulted in signifi-
cant progress towards understanding the phenomenon
of immunological tolerance. It has become evident that
despite the anatomical separation of the mother and fetus,
the induction of tolerance requires the recognition of fetal
antigens by maternal immune cells [2]. Tolerance induc-
tion involves several mechanisms, including immuno-
logical ignorance [3], T cell apoptosis and anergy [4,5],
and immunosuppression mediated by both regulatory cells* Correspondence: oleplina@mail.ru
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unless otherwise stated.[6,7] and cytokines [8,9]. Furthermore, a key role for den-
dritic cells (DCs) in immune tolerance that occurs during
pregnancy has been proposed.
DCs are best known as cells that can induce an adaptive
immune response [10,11], although DCs were also re-
cently shown to be capable of suppressing immune re-
sponses [12]. Initially, this tolerogenic activity was thought
to be associated with an immature state of DCs or with
the plasmacytoid DC subset [12,13]. However, subsequent
studies showed that intermediate and mature DCs can
also exhibit tolerogenic properties [14,15], and DC pheno-
types can be influenced by various anti-inflammatory and
immunosuppressive mediators [16-18]. DCs can acquire
tolerogenic features upon exposure to prostaglandin E2,
vitamin D3, HLA-G molecules, IL-21, IL-16, IL-4, throm-
bopoietin, M-CSF, G-CSF, HGF, VIP (vasoactive intestinal
peptide), or TSLP (thymic stromal lymphopoietin), whichral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Additionally, many apoptotic trophoblast cells enter the
circulation during pregnancy, and their engulfment might
also induce tolerogenic activity in DCs [21].
The functional activity of DCs has been shown to be
controlled by hormones, including glucocorticoids and
sex hormones, such as chorionic gonadotropin, estrogens,
and progesterone, which can increase the tolerogenic po-
tential of DCs [22-27]. Therefore, it was suggested that
hormones can modulate DCs and that the microenviron-
ment represents a key factor that can trigger and regulate
immunological tolerance [28]. Accordingly, dysfunction in
hormone secretion pathways can significantly affect the
tolerogenic potential of DCs.
Previously, we showed that pregnant women with ele-
vated levels of DHEAS, which results from minor forms
of adrenal hyperandrogenia (HA), exhibit immune ab-
normalities. In particular, they show a reduced number
of CD4+CD25+ regulatory T cells and an increased num-
ber of activated NK cells compared to women with a
normal pregnancy [29]. Because similar immune abnor-
malities have been described in women with recurrent
miscarriages [30,31], we suggested that immune dysfunc-
tion might be the cause of the increased abortion rate in
pregnant women with elevated levels of DHEAS [32,33].
The stimulatory effect of DHEAS on the immune system
that results in the activation of natural killer cells (NK
cells) and Th1 cells is well-known [34]. We have also
shown that DHEAS can induce the in vitro maturation
and Th1-stimulating activity of DCs [35]. Therefore, we
suggest that immune dysfunctions in pregnant women
with increased levels of DHEAS could result from im-
paired immunological tolerance, and the reduction in
the tolerogenic potential of DCs might be caused by ele-
vated concentrations of DHEAS.
To test this hypothesis, we studied the phenotypic and
functional properties of monocyte-derived DCs in non-
pregnant women, women with a normal pregnancy, and
pregnant women with elevated levels of DHEAS. We




This study included three groups of women (Table 1). The
control group included 42 fertile non-pregnant women
(who had at least one successful pregnancy and no previ-
ous abortions) whose menstrual cycles were regular (mean
age 30.2 ± 0.2 years). All women in the control group had
normal serum levels of DHEAS. Study group I included 66
healthy pregnant women who did not have any infectious
or endocrine diseases, or clinical signs of hyperandrogen-
ism, and who exhibited normal serum levels of DHEAS
(<1.8 mg/ml). Study group II included 44 pregnant womenwith elevated levels of DHEAS (>1.8 mg/ml) that could be
attributed to minor forms of adrenal hyperandrogenia and
were not associated with polycystic ovaries. All pregnant
women were under 22 weeks of gestation. The groups of
pregnant women were comparable in age (26.1 ± 0.1 and
26.9 ± 0.1 years, respectively) and gestation period (14.2 ±
0.2 and 15.1 ± 0.1 weeks, respectively). All patients partici-
pating in this study had no acute exacerbations of chronic
diseases, acute infections, or other endocrine disorders.
All individuals provided written informed consent to
participate in this study that was approved by the local
ethical committee of the Institute of Fundamental and
Clinical Immunology.
Generation of DCs
Peripheral blood mononuclear cells (MNCs) were ob-
tained by density gradient centrifugation (Ficoll-Paque,
Sigma–Aldrich) of heparinized whole blood samples.
DCs were generated by culturing the plastic-adherent
MNC fraction in 6-well plates (Nunclon, Denmark) in
RPMI-1640 medium (Sigma–Aldrich) supplemented with
0.3 mg/ml L-glutamine, 5 mM HEPES buffer, 100 μg/ml
gentamicin, and 5% fetal calf serum (FCS, Sigma–Aldrich)
in the presence of recombinant human GM-CSF (40 ng/
ml, Sigma–Aldrich) and rIFN-α (Roferon-A, 1000 U/ml,
Roche, Switzerland) for 4 days at 37°С in a 5% СО2
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stimulated with 10 μg/ml lipopolysaccharide (LPS E. coli
0114: B4, Sigma–Aldrich) as a maturation stimulus for
an additional 24 h. In some experiments, DHEAS
(Sigma–Aldrich, 10−6 М) was added to the DC culture
along with LPS. The viability of IFN-DCs, as determined
by Trypan blue exclusion, was at least 93–95% in all cases.
Flow cytometric analysis
Flow cytometry was performed using FACS Calibur and
CellQuest software (BD Becton Dickinson). DC pheno-
types were determined following direct single- or two-
color staining with FITC-, PE- or PerCP-conjugated mAb
specific for CD83, CD25, HLA-DR, CD14, or B7-H1 (BD
PharMingen). In each experiment, isotype-matched con-
trol mAbs were included to measure non-specific back-
ground staining.
Analysis of intracellular expression and production of
cytokines
The capacity of DCs to activate T cell cytokine produc-
tion was tested in allogeneic mixed lymphocyte cultures
(MLCs). Freshly isolated monocyte-depleted allogeneic
MNCs (1 × 105 per well) were cultured in complete culture
medium supplemented with 10% FCS with or without DCs
(1 × 104 per well) in 96-well plates for 72 h. For the last 18
h of culture, 10 μg/ml Brefeldin A (Sigma–Aldrich) was
added. Cells were harvested, washed, and incubated with
APC-conjugated anti-CD3 mAb (BD Pharmingen) at room
temperature for 15 min. Cells were then permeabilized
with 0.2% Tween-20 (Sigma–Aldrich), stained with FITC-
labeled anti-IFN-γ or PE-labeled anti-IL-4 mAb (BD Phar-
mingen), and analyzed by flow cytometry.
To measure IFN-γ and IL-4 secretion by T cells, after
5 days supernatants of co-cultured MNCs and allogenic
IFN-DCs (at a MNC-to-DC ratio of 10:1) were collected
and assayed using IFN-γ and IL-4 ELISA kits according
to the manufacturer’s instructions (Vector-Best, Russia).
Analysis of apoptosis
To analyze the apoptosis of CD3+CD4+ and CD3+CD8+
Т cells, IFN-DCs were co-cultured with 1 × 105 allogenic
MNCs from healthy donors in 96-well round-bottom
plates at a DC-to-MNC ratio of 1:10. After 3 days of
incubation, cells were harvested, washed, and incubated
with APC-conjugated anti-CD3 and PerCP-conjugated
anti-CD4 Abs (BD Pharmingen) at room temperature for
15 min. The percentage of apoptotic cells was determined
using a FITC-conjugated Annexin V Apoptosis Detection
Kit I according to the manufacturer’s recommendations
(BD Pharmingen). Apoptotic cells were identified by the
binding of FITC-conjugated Annexin V and PI within
the CD3+CD4+ or CD3+CD8+ (CD4−) gates. Data were
expressed as the percentage of positive cells among totalCD3+CD4+ and CD3+CD8+ Т cells. At least 10,000 events
were gathered from each sample.
Statistical analysis
Statistical analysis was performed using Statistica 6.0
software for Windows (StatSoft Inc.). Data were expressed
as means ± SE. The nonparametric Mann–Whitney U test
was used to determine statistically significant differences.
A threshold for significance of p < 0.05 was used.
Results
Because the functional activity of DCs largely depends on
their maturity, we compared surface marker expression of
DCs generated in normal pregnant women (NP-DCs) and
pregnant women with hyperandrogenia (HA-DCs). DCs
of non-pregnant fertile women were used as a control
(control DCs). As shown in Figure 1, a two-fold lower per-
centage of CD83+ cells (a marker of mature monocyte-
derived DCs) and CD25+ cells (a marker of activated ma-
ture DCs) were generated from normal pregnant women
than from non-pregnant controls (рU < 0.01). Meanwhile,
HA-DCs were not found to have a reduced percentage of
CD83+ and CD25+ cells as compared to control DCs.
Accordingly, the rate of CD83+ and CD25+ cells in the
HA-DC population was two-fold higher than in NP-DCs.
The percentage of CD14+ cells (a monocyte/macrophage
marker) in HA-DC cultures was also significantly higher
than in NP-DCs. To explain the cause of the simultan-
eous increase in CD83+ and CD14+ cells, we character-
ized the co-expression of these molecules by DCs. In
cultures of NP-DCs, about half of CD83+ cells co-
expressed CD14 (4.3% ± 0.9%) on their surface. The pro-
portion of CD14+CD83+ cells in HA-DCs was three
times higher than that of women with a normal preg-
nancy (up to 14.0% ± 2.5%, pU < 0.01), and this explained
the observed simultaneous increase in both CD14+ and
CD83+ cells in the HA-DC populations.
To assess whether the impaired maturation/activation
state of DCs could affect their functional activity, we fur-
ther investigated the ability of DCs to stimulate T cell
production of IFN-γ and IL-4 in a MLC. DCs from non-
pregnant controls (Table 2) stimulated a five-fold increase
in the number of CD3+IFN-γ+ T cells, but negligibly influ-
enced the number of CD3+IL-4+ T cells. Similar data were
also obtained from an analysis of IFN-γ and IL-4 secre-
tion. The concentration of IFN-γ in the supernatant of
MLC, stimulated by DCs from non-pregnant women,
was significantly higher than that in cultures without
DCs. However, DCs did not significantly stimulate IL-4
secretion.
Compared to control DCs, NP-DCs did not induce an
increased number of CD3+IFN-γ+ T cells and stimulated
less secretion of IFN-γ, but did induce almost a three-fold
increase in CD3+IL-4+ T cells and moderately enhanced
Figure 1 (See legend on next page.)
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Figure 1 Phenotypic characteristics of IFN-α-DCs in normal pregnant women and pregnant women with hyperandrogenia. IFN-α-DCs
were analyzed by flow cytometry for the expression of DC-related surface antigens in non-pregnant reproductive aged women (control group),
normal pregnant women (NP-women), and pregnant women with hyperandrogenia (HA-women). (A) Histograms represent the expression of the
indicated molecules (bold-line histograms) and the corresponding isotype controls (grey-filled histograms) in individual experiments. The relative
percentage of positive cells (%) among the DCs are presented as means (± SE). (B) Gated HLA-DR+ IFN-α-DCs were analyzed for CD14 and CD83
staining. Representative stainings of IFN-α-DCs from NP-women (left, dot plots) and HA-women (right, dot plots) are shown.
Chernykh et al. BMC Immunology  (2015) 16:2 Page 5 of 9IL-4 production. HA-DCs also stimulated the increase in
CD3+IFN-γ+ T cells and secretion of IFN-γ, although their
stimulatory effect was significantly lower than that of con-
trol DCs. Additionally, HA-DCs retained the ability to
stimulate T2-responses, in particular to induce CD3+IL-4+
T cells and increase IL-4 secretion.
To clarify whether the enhanced capacity of HA-DCs
to stimulate IFN-γ production by T cells could be attrib-
uted to increased level of DHEAS, we studied the direct
effects of the hormone on the T1-stimulated activity of
NP-DCs. Treatment of NP-DCs with DHEAS induced
pronounced Th1-stimulatory activity. Levels of IFN-γ in
MLCs induced by DHEAS-modified NP-DCs were more
than two-fold higher than that in the MLC, which were
induced by intact NP-DCs (344 ± 160 vs. 144 ± 90 pg/ml;
PU < 0.05). Therefore, our findings suggest that DHEAS
in vitro has a pronounced up-regulating effect on Th1-
stimulating capacity of NP-DCs.
Notably, DC tolerogenic activity might be associated
with both the induction of Th2-responses and the ability
of T cells to promote the apoptosis/anergy of cytotoxic T
cells. Indeed, we recently found that donor IFN-α-DCs
can induce T cell apoptosis via the PD-1/PD-L1 pathway,
and enhanced expression of PD-L1 (B7-H1) on DCs could
significantly increase their pro-apoptogenic activity inTable 2 T1/T2-stimulatory activity of IFN-α-DCs
Culture conditions Intracellular expression an
Control group (n = 10)
Value SI
CD3+ IFN-γ+ (%) 0 1.5 ± 0.2
+ DCs 5.9 ± 0.6 5.2 ± 0.9
CD3+ IL-4+ (%) 0 1.7 ± 0.1
+ DCs 2.1 ± 0.4 1.3 ± 0.2
IFN-γ (pg/ml) 0 18.2 ± 5.7
+ DCs 353 ± 41 22.2 ± 3.1
IL-4 (pg/ml) 0 1.0 ± 0.08
+ DCs 2.0 ± 1.0 2.0 ± 1.0
Donor MNCs were co-cultured with allogenic IFN-α-DCs from non-pregnant women
(HA) for 72 h at an MNC-to-DC ratio of 10:1. For the final 18 h of culture, 10 μg/ml
within the CD3+ gate by flow cytometry. To determine the levels of cytokine produ
co-culturing donor MNCs and allogenic IFN-α-DCs from the control group, NP-wom
production of IL-4 and IFN-γ using specific ELISA kits. Data are presented as mean (
the indicated number of independent experiments. SI indicates the stimulation ind
intracellular cytokine expression (%) by MNCs in the presence or absence of DCs. *,
compared to the NP-women group. Significant differences were detected using theimmunopathology [36,37]. Therefore, we compared the
expression of B7-H1 and assessed DC cytotoxic activity in
normal pregnant women and pregnant women with HA.
The percentage of B7-H1+ cells in the HLA-DR+ subset
of control DCs (Figure 2) varied from 20% to 54%, and the
average was 37.3% ± 3.4%. In normal pregnancy, the num-
ber of B7-H1+ DCs was significantly higher and reached
an average of 85% ± 2.6%. The number of B7-H1+ cells in
HA-DC cultures was significantly lower than in NP-DC
cultures (73.7% ± 2.7% vs. 85% ± 2.6%, рU = 0.027). Repre-
sentative histograms of DC expression of HLA-DR and
B7-H1 in women with a normal pregnancy or a pregnancy
with HA are shown in Figure 3.
To analyze DC cytotoxic activity of NP-DCs and HA-
DCs, we studied the amount of CD4+ and CD8+ T-cell
apoptosis in MLC that was induced by these DCs (Table 3
and Figure 4). NP-DCs and HA-DCs had similar pro-
apoptogenic activity against CD3+CD4+ T cells. The num-
ber of apoptotic (Annexin V+/PI−) CD3+CD4+ T cells in
MLC that were induced by DCs from pregnant women in
both groups significantly exceeded the number of apop-
totic cells in the controls (monocyte-depleted MNC cul-
tures without DCs), but did not differ from each other.
However, the percentage of apoptotic (Annexin V+/PI−)
CD3+CD8+ T cells in MLC that were induced by NP-DCsd production of the cytokines IFN-γ and IL-4
NP women (n = 8) HA women (n = 8)
Value SI Value SI
1.8 ± 0.5 1.8 ± 0.5
1.5 ± 0.27** 1.1 ± 0.2** 2.5 ± 0.3**# 2.0 ± 0.4**#
2.6 ± 0.4 3.3 ± 0.5
8.6 ± 1.0** 3.5 ± 0.4** 7.4 ± 1.0** 2.4 ± 0.5*
16.5 ± 2.8 16 ± 3.0
63.4 ± 27.8** 3.4 ± 0.9** 218 ± 69* # 13.5 ± 3.1*#
1.0 ± 0.09 1.0 ± 0.12
4.6 ± 2.2 4.6 ± 2.2 5.4 ± 2.0* 5.4 ± 2.0*
(control), normal pregnant women (NP), or hyperandrogenia pregnant women
Brefeldin A was added. Intracellular expression of IFN-γ and IL-4 was detected
ction by MNCs, cell-free supernatants were collected after 5 days of
en, or HA-women (at a MNC-to-DC ratio of 10:1) and were assessed for
± SE) cytokine concentrations (pg/ml) or the percentage of CD3+ cells from
ex, which was calculated as the ratio of cytokine concentrations (pg/ml) or
pU < 0.05, **, pU < 0.01, compared to the control women group;
#, pU < 0.05,
Mann–Whitney U test.
Figure 2 Expression of B7-H1 molecules by IFN-α-DCs from healthy donors (HD), normal pregnant (NP) women, and pregnant women
with hyperandrogenia (HA). Data are presented as means (± SE) percentage of cells positive for B7-H1 staining among all IFN-α-DCs expressing
HLA-DR. *, pU < 0.05 indicates a significant difference compared to healthy donors (n = 12); #, pU < 0.05 indicates a significant difference between
groups of NP-women (n = 6) and HA-women (n = 8); comparisons were made using the Mann–Whitney U test.
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duced by HA-DCs.
Discussion
DCs represent unique antigen-presenting cells that are
capable of inducing both an immune response and a
state of immunological tolerance [10]. The presence of
DCs in the decidua, where direct interactions between
fetal and maternal cells occurs, makes these cells candi-
dates to be key regulators of immune tolerance in preg-
nancy [38,39]. Nevertheless, DCs in human pregnancy
are not well studied and findings are often contradictory.
In this paper, we demonstrated for the first time that
DHEAS, whether elevated during pregnancy in vivo or
added in vitro, results in the induction of DC maturation
and type 1 T cell stimulatory activity and reduces theFigure 3 Expression of B7-H1 by IFN-α-DCs from healthy donors
or pregnant women. Representative data from experiments performed
with IFN-α-DCs from healthy donors (HD, left), normal pregnant
women (NP, middle), or pregnant women with hyperandrogenia (HA,
right) are shown.apoptosis-inducing activity of monocyte-derived DCs.
Monocytes represent a major source of DC precursors
and can differentiate into DCs upon exposure to GM-CSF
in combination with IL-4 (IL-4-DCs) or IFN-α (IFN-α-
DCs) [40,41]. Because DHEAS has been reported to inhibit
the secretion of IL-4 [42], we chose a DC generation proto-
col using GM-CSF and IFN-α. The choice of this protocol
was also motivated by the fact that unlike the IL-4-DCs
that predominantly activate Th1-responses, IFN-α-DCs
can activate both Th1- and Th2-responses [43,44] and
possess more pronounced cytotoxic activity [45]. These at-
tributes provide the opportunity to assess the effects of
DHEAS on the Th1- and Th2-stimulating activity and
cytotoxic effects of DCs.
Our data have shown that in a healthy pregnancy,
monocyte-derived IFN-α-DCs possess “tolerogenic” po-
tential, as evidenced by a less mature phenotype and
increased priming of type 2 (IL-4) T cell responses com-
pared to DCs from non-pregnant women. Whereas DCs
from non-pregnant women induce activated T cell pro-
duction of IFN-γ, DCs from women with a normal preg-
nancy predominantly stimulated the production of IL-4.
Our data are consistent with the findings of other groups,
which demonstrate that the immature phenotype of mye-
loid DCs, reduced expression of co-stimulatory molecules
(CD86 and CD80), and the expression of immunoglobulin-
like transcript 3 (ILT-3) were involved in the induction of
tolerance and the higher T2-stimulatory activity of decid-
ual DCs in healthy pregnant women [46-48]. Regarding the
properties of circulating DCs, Della Bella et al. showed that
despite the higher expression of co-stimulatory molecules
and the secretion of pro-inflammatory and regulatory cyto-
kines, DCs in a healthy pregnancy were characterized by a
low HLA-DR expression, which indicates the “incomplete”







(NP), n = 6
MNCs + DCs
(HA), n = 8
CD3+CD4+ 0.19 ± 0.05 4.7 ± 1.0* 5.3 ± 1.2*
Т cells 0.25 3.6 3.92
CD3+CD8+ 0.17 ± 0.04 15.02 ± 0.3* 11.19 ± 0.9*#
Т cells 0.13 15.0 11.23
Untreated MNCs from healthy donors (control) and MNCs co-cultured with
IFNα-DCs from normal pregnant (NP) women or pregnant women with
hyperandrogenia (HA) at a MNC-to-DC ratio of 10:1 for 3 days were analyzed
for Annexin V/PI double positivity by flow cytometry. Data are presented as
mean (± SE) percentages and medians of apoptotic Annexin V+/PI− cells within
the CD3+CD4+ or CD3+CD8+ (CD4−) gates. *, pU <0.05, compared to the control
group; #, pU < 0.01, a significant difference between the NP pregnant women
and HA pregnant women groups; differences were detected using the
Mann–Whitney U test.
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pregnant women was added to control DCs, it induced a
DC phenotype associated with low allo-stimulatory activity
[49]. For monocyte-derived DCs, Bachy et al. showed that
DCs generated by culturing cells from a normal pregnancy
in the presence of GM-CSF and IL-4 were phenotypically
less mature and characterized by reduced IL-12 and in-
creased IL-10 secretion [50]. However, these authors did
not investigate the capacity of these DCs to activate T1 and
T2 immune responses.
The second important finding of this study is that DCs
from women with elevated levels of DHEAS exhibit no
signs of immaturity and, along with a capacity to stimu-
late the T cell secretion of IL-4, can also activate the pro-
duction of IFN-γ. Because DHEAS, when added to DCs
derived from women with a normal pregnancy, induced
T1-stimulatory activity, we suggest that the capacity ofFigure 4 T cells undergo enhanced apoptotic cell death when culture
co-cultured with 1 × 105 allogenic MNCs from healthy donors at a 1:10 rati
CD3+CD4+ T cells were analyzed for Annexin V and PI double positivity. Re
IFN-DCs from normal pregnant (NP) women (middle), and MNCs co-culture
(right) are shown.HA-DCs to prime type 1 T cell responses in pregnant
women with HA could be explained by the elevated levels
of this hormone.
Another interesting aspect of this study is our analysis
of DC cytotoxic activity. Previously, we showed that IFN-
α-DCs from healthy donors can induce the apoptosis of
activated NK cells, and the maturation of IFN-α-DCs
upon exposure to DHEAS is associated with the down-
regulation of cytotoxic activity [51]. Furthermore, we
showed that IFN-α-DCs could induce T cell apoptosis,
which is largely mediated through the PD-L1 (B7-H1)/
PD-1 signaling pathway [47]. As B7-H1 expression on
IFN-α-DCs declines along with DC maturation [52], we
suggest that DC maturation induced by DHEAS could de-
crease DC cytotoxic potential against T cells. Indeed, our
study showed that in a normal pregnancy DCs were char-
acterized by increased expression of B7-H1 compared to
control DCs. Furthermore, in pregnant women with ele-
vated levels of DHEAS, the number of B7-H1+ DCs was
significantly lower than in a normal pregnancy. Moreover,
the reduced expression of B7-H1 was associated with
lower DC cytotoxicity against CD3+CD8+ T cells. Over-
all, these findings suggest that in pregnant women with
elevated levels of DHEAS, the tolerogenic properties of
DCs were significantly reduced, which could contribute
to impaired “immunosuppressive” re-arrangements of
the immune system in HA.
The reduced tolerogenic potential of DCs has been pro-
posed as one of the causative factors of abnormal preg-
nancy in recurrent pregnancy loss [39] and pre-eclampsia
[53]. However, impaired DC functions in pregnant women
with increased levels of DHEAS are described herein for
the first time. Our findings shed new light on immune–d with IFN-α-DCs from pregnant HA+ women. IFN-α-DCs were
o. After 3 days, apoptosis was evaluated by flow cytometry. Gated
presentative cases of untreated MNCs (left), MNCs co-cultured with
d with IFN-α-DCs from pregnant women with (HA) hyperandrogenia
Chernykh et al. BMC Immunology  (2015) 16:2 Page 8 of 9endocrine interactions and their importance in normal
and complicated pregnancies.
Conclusions
We report that in healthy pregnancy IFN-α-induced
monocyte-derived DCs are characterized by the imma-
ture phenotype, the potent ability to stimulate type 2 T
cell responses and to induce T cell apoptosis. In contrast,
DCs from pregnant women with hyperandrogenia have a
mature phenotype, are able to stimulate both type 1
(IFN-γ) and type 2 (IL-4) T cell responses, and differ by
lower apoptosis-inducing activity. In addition, DHEAS,
when added in vitro to DCs from healthy pregnants, in-
duces the maturation of DCs and increases their ability to
activate type 1 T cell responses. This indicates a reduced
tolerogenic potential of DCs from pregnant women with
HA and reveals a new mechanism involved in the hormo-
nal regulation of DCs mediated by DHEAS.
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